Btobioinnovation.com  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT   An Approval and an Inventive Step in Alzheimer’s Disease.     On July 6, 2023, the US FDA granted Full Approval for Eisai and Biogen’s LEQUEMBI (lecanemab-irmb), a 100 mg/ml injection for intravenous use, for the treatment of Alzheimer’s disease. LEQUEMBI […]